Deutsche Bank starts Climb Bio at Buy, citing compelling autoimmune pipeline

What happened: Deutsche Bank initiated coverage of Climb Bio Inc (NASDAQ:CLYM) with a Buy rating and a $28 price target, citing the company's autoimmune pipeline. Shares rallied over 10% in Tuesday morning trading. Key numbers: Buy rating, $28 price target, shares up over 10%, at least four clinical updates expected in Q4 2026, Phase 2 results for CLYM116 expected mid-2027. Why it matters: Analyst David Hoang said the market is underestimating the pipeline's commercial potential, and that the recent pullback, which he attributed to sector-wide pressure, offers an appealing entry point. Market: +9.8% today ($10.68), +184.8% YTD, 0.4x vol — as of 16:32 UTC

Deutsche Bank initiated coverage of Climb Bio Inc (NASDAQ:CLYM) with a Buy rating and a $28 price target, citing the company's autoimmune pipeline. Shares rallied over 10% in Tuesday morning trading.

Analyst David Hoang said the market is underestimating the pipeline's commercial potential, and that the recent pullback, which he attributed to sector-wide pressure, offers an appealing entry point. Market: +9.8% today ($10.68), +184.8% YTD, 0.4x vol — as of 16:32 UTC